Effect of African American race on hypertension management: A real-world observational study among 28 US physician practices

Ethnicity and Disease

Volumn 20, Issue 4, 2010, Pages 409-415

  Batson, Bryan ^c   Belletti, Daniel ^a   Wogen, Jenifer ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MedMentis Consulting LLC   (United States)

^c Hattiesburg Clinic   (United States)

Author keywords

Blood pressure control; Community based studies; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CAUCASIAN; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OBSERVATIONAL STUDY; UNITED STATES; ADOLESCENT; CLINICAL PRACTICE; CLINICAL TRIAL; ETHNOLOGY; MIDDLE AGED; MULTICENTER STUDY; OBESITY; STATISTICS;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PHYSICIAN'S PRACTICE PATTERNS; YOUNG ADULT;

EID: 79952685095     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Giles T., Aranda J.M., Suh D.C., Choi I.S., et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens. 2007;9:345-354.
2. Suh D.C., Choi I-S, Plauschinat C., Kwon J., Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complications. 2009;Aug 26 [epub ahead of print].
3. Saydah S., Cowie C., Eberhardt M.S., DeRekeneire N., Narayan K.M. Race and ethnic differences in glycemic control among adults with diagnosed diabetes in the United States. Ethn Dis. 2007;17:529-535. (Pubitemid 47606763)
4. Ong K.L., Cheung B.M.Y., Man Y.B., Lau C.P., Lam K.S.L. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49:69-75. (Pubitemid 46360343)
5. Chobanian A., Bakris G., Black H. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572. (Pubitemid 37430158)
6. Douglas J.G., Bakris G.L., Epstein M., et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163: 525-541. (Pubitemid 36314340)
7. Saunders E., Weir M.R., Kong B.W., et al. A comparison of the efficacy and safety of a bblocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive Blacks. Arch Intern Med. 1990;150:1707-1713. (Pubitemid 20240985)
8. Materson B.J., Reda D.J., Williams D. Lessons from combination therapy in Veterans Affairs Studies. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1996;9:187S-191S.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2197.
10. He J., Whelton P.K. Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138(3 Pt 2):211-219.
11. Cushman W.C., Reda D.J., Perry H.M., et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 2000;160:825-831. (Pubitemid 30165243)
12. Belletti D.A., Zacker C., Wogen J. Effect of cardiometabolic risk factors on hypertension management: A cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol. 2010;9(7).
13. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288:2421-2431. (Pubitemid 35340538)
14. Bakris G.L. Maximizing cardiorenal benefit in the management of hypertension: Achieve blood pressure goals. J Clin Hypertens. 1999; 1:141-147.
15. Ferdinand K.C. Underutilization of angiotensin- converting enzyme inhibitors in high-risk blacks: A case of missed opportunities. J Clin Hypertens. 2009;11:648-650.
16. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
17. Papademetriou V., Kaoutzanis C., Dumas M., et al. Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease. J Clin Hypertens. 2009;11:621-626.